IGCS Education360 Podcast

Vulvar Cancer with HIV Nursing Tumor Board

IGCS nursing workgroup bimonthly tumor board and discussed nursing care options for a vulvar cancer patient with HIV experiencing incomplete treatment and gaps in follow-up.  
Case presentation by Biemba Maliti (Zambia)Moderated by Anne Mellon, RN (Australia), Chrissy Donovan, RN, NP (USA), and Sarah Belton, RN (Ireland)Join future IGCS nursing tumor boards by registering through iECHO.  If have a case you would like to present for discussion, please contact education@igcs.org.  

Immunotherapy Toxicities Nursing Tumor Board

IGCS nursing workgroup held their first tumor board and discussed nursing care options for a cervical cancer patient experiencing immunotherapy toxicities. 
Case presentation by Sarah Belton, RN (Ireland)Moderated by Anne Mellon, RN (Australia) and Chrissy Donovan, RN (USA)Interested in joining future IGCS nursing tumor boards, or have a case you would like to present for discussion, please contact education@igcs.org.  

Journal Club: Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Listen to a new Journal Club with PI Dr. Brian Slomovitz and moderator Dr. Leslie Randall as they discuss details on the New England Journal of Medicine published article Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Click here to read the article
Presented byBrian SlomovitzDirector of Gynecologic Oncology Co-Chair, Cancer Research CommitteeMount Sinani Medical CenterUSA
Moderated byLeslie RandallDirector of Gynecologic Oncology Clinical Research and Gynecologic Cancer Service LineInova Schar Cancer InstituteInova Health System USA
Supported in part by Pfizer | Genmab
 

Multidisciplinary Conversations with Radiation Oncologist Carien Creutzberg

IGCS Education360 Radiation Oncology Workgroup, chaired by Dr. Pearly Khaw, interview with Professor Carien Creutzberg, recipient of the IGCS 2024 Lifetime Achievement Award. She discusses her pioneering work and the significance of international collaboration. Creutzberg reflects on the evolution of research questions in clinical trials, the integration of molecular and immunotherapy advancements, and the importance of multidisciplinary teams in enhancing patient care and treatment outcomes.

Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type

Listen to Dr. Robert Coleman (USA) and Dr. Floor Backes (USA) discuss a new trial in progress enrollment information for advanced and recurrent endometrial cancer - Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042.
Video available at IGCS Education360 Learning Portal - https://edu360.igcs.org/URL/AU_05152024

Early Career Workshop 2022 - Hear from the Gynecologic Oncology Editors

Let’s Hear from the Gynecologic Oncology Editors of:
• Obstetrics & Gynecology - Jason Wright (USA)
• American Journal of Obstetrics and Gynecology- Larry Copeland (USA)
• Gynecologic Oncology and Gynecologic Oncology Reports - Susan Modesitt (USA)
• International Journal of Gynecological Cancer - Pedro Ramirez (USA)
Moderator:
Rhonda Farrell (Australia)

The ABCs of ADCs

In this episode of the IGCS Education 360 Podcast entitled: The ABCs of ADCs, Dr. Brad Monk, from the Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network) and the University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, USA and Medical Director US Oncology Research Network - Gynecologic Program is joined by Dr. Kathleen Moore, Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics Associate Director Clinical Research, Director, Oklahoma TSET Phase I Program, Stephenson Cancer Center and Associate Professor, Section of Gynecologic Oncology At the University of Oklahoma Health Sciences Center to talk about Antibody-Drug Conjugate or ADCs.
ADC’s are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. In this episode you will learn the following:
• How exactly ADCs work?
• What are the targets for ADCs?
• The differences between ADC, MOA, and the differences between some of the ADCs – high DAR, and the controlled bystander effect
• Importance of an optimal diagnostic assay (H-score vs PS2+ vs TPS) NS the importance of a correct dosing regimen
• And finally payload in relation to ADC’s and current ongoing studies.